Interleukin-27 Receptor Limits Atherosclerosis in Ldlr −/− Mice
نویسندگان
چکیده
منابع مشابه
Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice.
Chronic inflammation in arterial wall that is driven by immune cells and cytokines plays pivotal roles in the development of atherosclerosis. Interleukin 27 (IL-27) is a member of the IL-12 family of cytokines that consists of IL-27p28 and Epstein-Barr virus induced gene 3 (EBI3) and has anti-inflammatory properties that regulate T cell polarization and cytokine production. IL-27-deficient (Ldl...
متن کاملAn Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice
IκBNS is a nuclear IκB protein which negatively regulates nuclear factor-κB activity. We demonstrated that IκBNS deficiency accelerates atherosclerosis in LDL receptor-deficient (LDLr-/-) mice via increased interleukin (IL)-6 production by macrophages. Previous studies showed that the increase in IL-6 might contribute to the development of atherosclerotic lesions. However, whether an anti-mouse...
متن کاملAntibodies against electronegative LDL inhibit atherosclerosis in LDLr-/- mice.
In order to determine the effect of antibodies against electronegative low-density lipoprotein LDL(-) on atherogenesis, five groups of LDL low receptor-deficient (LDLr-/-) mice (6 per group) were immunized with the following antibodies (100 microg each): mouse anti-LDL(-) monoclonal IgG2b, rabbit anti-LDL(-) polyclonal IgG or its Fab fragments and mouse irrelevant monoclonal IgG and non-immuniz...
متن کاملEffect of BSN272 on Hyperlipidemia and Atherosclerosis in LDLr-/- Mice
This study was designed to compare the effects of D-tagatose with BSN272 on serum lipids and prevention of atherosclerosis in LDLr mice. BSN272 is a combination drug of D-tagatose and polydatin (trans piceid). LDLr mice were divided into four groups and were all fed a standard chow. Mice were dosed by gavage and received water (group 1), a glucose/fructose mixture (group 2), or glucose/fructose...
متن کاملPravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.
Pravastatin is a lipid-lowering agent that attenuates atherosclerosis. However, the multifactorial pathogenesis of atherosclerosis requires other drugs with different anti-atherogenic mechanisms. We chose sarpogrelate as an anti-platelet agent and a novel component of a complex drug with pravastatin due to its high potential but little information on its beneficial effects on atherosclerosis. L...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Research
سال: 2012
ISSN: 0009-7330,1524-4571
DOI: 10.1161/circresaha.112.277525